- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Beigene Ltd (6160)
Beigene Ltd stock price live, this page displays HK 6160 stock exchange data. View the 6160 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Beigene Ltd real time stock price chart below.
What Is the Beigene Ltd Stock Price Today?
The Beigene Ltd stock price today is 155.50.
What Is the Stock Symbol for Beigene Ltd?
The stock symbol for Beigene Ltd is "6160."
What Stock Exchange Does Beigene Ltd Trade On?
Beigene Ltd is listed and trades on the Hong Kong stock exchange.
Is Beigene Ltd a Good Stock to Buy?
Determining whether Beigene Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 6160 quote. (ISIN: KYG1146Y1017)
What Is the Beigene Ltd Stock Price Today?
The Beigene Ltd stock price today is 155.50.
What Is the Stock Symbol for Beigene Ltd?
The stock symbol for Beigene Ltd is "6160."
What Stock Exchange Does Beigene Ltd Trade On?
Beigene Ltd is listed and trades on the Hong Kong stock exchange.
Is Beigene Ltd a Good Stock to Buy?
Determining whether Beigene Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 6160 quote. (ISIN: KYG1146Y1017)
155.50
-2.10(-1.33%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
153.00
158.30
52 wk Range
75.45
174.80
6160 Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
153.00158.30
52 wk Range
75.45174.80
Beigene Ltd is currently considered to be trading at Fair valueExplore our list of undervalued stocks for hidden opportunities
Beigene Ltd is not on our AI-picked strategiesExplore current and previous stocks selected by AI
Try Warren AI research assistant for instant insights on Beigene LtdFrom metrics, to news, charts, and even a SWOT analysis - you can ask anything!
What you should know about Beigene LtdNet income is expected to grow this yearImpressive gross profit margins
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
6160 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
194.98
Upside
+25.39%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Beigene Company Profile
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
Compare 6160 to Peers and Sector
Metrics to compare | 6160 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6160PeersSector | |
|---|---|---|---|---|
P/E Ratio | −42.0x | −2.9x | −0.5x | |
PEG Ratio | −1.52 | −0.04 | 0.00 | |
Price/Book | 8.1x | 2.4x | 2.6x | |
Price / LTM Sales | 7.1x | 6.2x | 3.0x | |
Upside (Analyst Target) | 24.7% | 149.4% | 55.2% | |
Fair Value Upside | Unlock | 15.6% | 9.7% | Unlock |
Analyst Ratings
17 Buy
1 Hold
0 Sell
Ratings:
18 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 194.98
(+25.39% Upside)
Earnings
Latest Release
Feb 27, 2025
EPS / Forecast
-0.8553 / -0.5503
Revenue / Forecast
8.77B / 7.98B
FAQ
What Is the Beigene (6160) Stock Price Today?
The Beigene stock price today is 155.50.
What Stock Exchange Does Beigene Trade On?
Beigene is listed and trades on the Hong Kong stock exchange.
What Is the Stock Symbol for Beigene?
The stock symbol for Beigene is "6160."
What Is the Beigene Market Cap?
As of today, Beigene market cap is 210.63B.
What is Beigene Earnings Per Share?
The Beigene EPS is -6.12.
What Is the Next Beigene Earnings Date?
Beigene will release its next earnings report on 30 Apr 2025.
From a Technical Analysis Perspective, Is 6160 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.